文献速递浆细胞疾病

Wee1激酶抑制剂MK1775抑制多发性骨髓瘤细胞生长、减弱干性并与硼替佐米协同作用

The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
PubMed 文献 · Br J Haematol · 2020-04-21

研究探讨Wee1抑制剂MK1775对多发性骨髓瘤(MM)及其干细胞样细胞(MMSCs)的作用。Wee1高表达与MM患者生存差相关,MM模型和患者来源CD138+浆细胞对MK1775的生长抑制效应敏感。MK1775诱导S期DNA损伤、阻断复制并致凋亡,在体外、体内及原代CD138+细胞中减弱干性特征,并与硼替佐米协同;硼替佐米虽增加ALDH1+细胞,联用MK1775可消除该干性刺激效应。

要点

  • Wee1高表达与多发性骨髓瘤患者生存差相关
  • MK1775在MM模型和患者CD138+浆细胞中诱导S期DNA损伤和凋亡
  • MK1775减弱干性并与硼替佐米在体外和体内协同

核心结论

  • 抑制Wee1是MM有前景的靶向治疗策略,并为进一步在临床环境中研究MK1775抗骨髓瘤活性提供依据。

研究设计与样本

  • 研究使用多发性骨髓瘤模型和患者来源的CD138+浆细胞,进行体外和体内实验。

主要发现

  • Wee1高表达与多发性骨髓瘤患者生存差相关。
  • MM模型和患者来源CD138+浆细胞对MK1775的生长抑制效应敏感。
  • MK1775诱导Mus81-Eme1核酸内切酶介导的S期DNA损伤,阻断复制并导致凋亡。
  • MK1775在体外、体内和原代CD138+细胞中通过减少ALDH1+细胞比例和ALDH1表达减弱干性特征。
  • MK1775与硼替佐米联合在体外和体内协同;硼替佐米增加ALDH1+细胞,联用MK1775可消除该刺激效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma stem-like cells (MMSCs) are responsible for initiation and relapse, though novel treatment paradigms that effectively eradicate MMSCs are yet to be developed. Selective inhibition of the cell cycle regulatory kinase Wee1 by MK1775 is being explored as a potential anti-cancer therapeutic. We report that higher expression of Wee1 is correlated with poor survival in multiple myeloma (MM). The MM models and patient-derived CD138+ plasma cells are particularly sensitive to the growth-inhibitory effects of the Wee1 inhibitor MK1775. MK1775 induces Mus81-Eme1 endonuclease-mediated DNA damage in S-phase cell cycle that results in a blockade of replication and then apoptosis. Furthermore, MK1775 strongly suppresses the features of stemness in vitro, in vivo and in primary CD138+ cells by decreasing ALDH1+ cell fraction and the expression of ALDH1. In addition, co-treatment of MK1775 with bortezomib is synergistic in vitro and in vivo. Bortezomib, although it enhances ALDH1+ cells, when combined with MK1775 abrogates this stimulatory effect on stemness. Considering MM as an invariably incurable malignancy due to the presence of heterogenic myeloma stem-like cells, our study presents inhibition of Wee1 as a promising targeted therapy for MM and provides a compelling rationale to further investigate the activity of MK1775 against myeloma in clinical settings.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liang L, He Y, Wang H, et al. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma. Br J Haematol. 2020. PMID: 32314355. doi:10.1111/bjh.16614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。